Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Atreca Inc (BCEL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.082 +0.002    +3.06%
13:38:00 - Delayed Data. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 24,648
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.080 - 0.082
Atreca 0.082 +0.002 +3.06%

Atreca Inc Company Profile

 
Get an in-depth profile of Atreca Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

90

Equity Type

ORD

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Contact Information

Address 835 Industrial Road Suite 400
South San Francisco, 94070
United States
Phone 650 595 2595
Fax 650 453 2410

Top Executives

Name Age Since Title
William H. Robinson 54 2011 Director
Franklin M. Berger 73 2014 Independent Director
Brian G. Atwood 69 2013 Independent Chairman of the Board
Kristine M. Ball 50 2020 Independent Director
David Lacey 70 2016 Independent Director
Lindsey Rolfe 54 2019 Independent Director
Lawrence Steinman 74 2019 Chairman of External Scientific Advisory Board & Technical Advisor
Douglas Crawford - - Board Observer
Andrew Farnum - - Board Observer
Stephen R. Brady 52 2021 Independent Director
Stacey Ma 51 2021 Independent Director
John A. Orwin 58 2018 President, CEO, Director & Principal Financial Officer
Tito A. Serafini 61 2010 Founder & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BCEL Comments

Write your thoughts about Atreca Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
BADR Mas
BADR Mas Jul 29, 2021 7:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what?! -30% 😔😏
Fadi Issa
Issaf Jul 29, 2021 7:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
you mean -40%
Saqib Khan
SaqibKhan Apr 08, 2021 12:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
161789847934419.jpg
Get ready to get your tank full for the upward journey. A long wait is almost over..
현수 김
현수 김 May 15, 2020 12:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
should I buy now?
The Lost
The Lost Sep 24, 2019 1:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Let's try 1000 at market on 09/24/19
Filippo Edera
Filippo Edera Jun 20, 2019 5:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is this something we should buy? and why?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email